

Income statement

Three months ended 30 June 2015

	Total £m	Total \$m
TURNOVER	5,888	9,065
Cost of sales	(2,005)	(3,089)
Gross profit	3,883	5,976
Selling, general and administration	(2,541)	(3,910)
Research and development	(812)	(1,251)
Royalty income	62	96
Other operating income	(257)	(306)
OPERATING PROFIT	335	605
Finance income	12	18
Finance expense	(194)	(299)
Profit on disposal of interest in associates	1	11
Share of after tax losses of associates and joint ventures	(2)	(3)
PROFIT BEFORE TAXATION	152	332
Taxation	(37)	(76)
PROFIT AFTER TAXATION FOR THE PERIOD	115	256
Loss attributable to non-controlling interests	(34)	(53)
Profit attributable to shareholders	149	309
	115	256
EARNINGS PER SHARE	3.1p	4.8¢
Diluted earnings per share	3.1p	4.8¢

US dollar amounts shown above are a convenience translation of the sterling amounts. US dollar results for the six months to 30 June 2015 are calculated using average rates for the period. US dollar results for the three months to 30 June 2015 are calculated as the difference between these six month results translated into US dollars and US dollar results previously published for the three months to 31 March 2015.

Income statement

Six months ended 30 June 2015

	Total £m	Total \$m
TURNOVER	11,510	17,610
Cost of sales	(4,108)	(6,285)
Gross profit	7,402	11,325
Selling, general and administration	(4,766)	(7,292)
Research and development	(1,679)	(2,569)
Royalty income	139	213
Other operating income	8,455	12,936
OPERATING PROFIT	9,551	14,613
Finance income	44	67
Finance expense	(385)	(589)
Profit on disposal of interest in associates	844	1,292
Share of after tax profits of associates and joint ventures	21	32
PROFIT BEFORE TAXATION	10,075	15,415
Taxation	(1,922)	(2,941)
PROFIT AFTER TAXATION FOR THE PERIOD	8,153	12,474
Loss attributable to non-controlling interests	(85)	(130)
Profit attributable to shareholders	8,238	12,604
	8,153	12,474
EARNINGS PER SHARE	170.7p	261.2¢
Diluted earnings per share	169.2p	258.9¢

US dollar amounts shown above are a convenience translation of the sterling amounts. US dollar results for the six months to 30 June 2015 are calculated using average rates for the period. US dollar results for the three months to 30 June 2015 are calculated as the difference between these six month results translated into US dollars and US dollar results previously published for the three months to 31 March 2015.

Pharmaceuticals and Vaccines turnover

Three months ended 30 June 2015

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Respiratory	1,467	704	369	394	2,259	1,083	569	607
<i>Anoro Ellipta</i>	15	12	3	-	23	19	4	-
<i>Avamys/Veramyst</i>	59	7	22	30	91	11	34	46
<i>Flixotide/Flovent</i>	159	100	22	37	244	153	34	57
<i>Relvar/Breo Ellipta</i>	53	19	19	15	82	29	30	23
<i>Seretide/Advair</i>	960	484	267	209	1,479	745	412	322
<i>Ventolin</i>	160	81	28	51	246	125	43	78
Other	61	1	8	52	94	1	12	81
Cardiovascular, metabolic and urology (CVMU)	242	102	66	74	373	157	102	114
<i>Avodart</i>	192	66	66	60	296	102	102	92
Other	50	36	-	14	77	55	-	22
Immuno-inflammation	56	51	3	2	87	79	5	3
<i>Benlysta</i>	56	51	3	2	87	79	5	3
Other	-	-	-	-	-	-	-	-
Oncology	19	(2)	(1)	22	32	(2)	-	34
Other pharmaceuticals	542	61	138	343	835	94	213	528
Dermatology	105	10	34	61	162	16	53	93
<i>Augmentin</i>	143	-	37	106	220	-	57	163
Other anti-bacterials	42	2	12	28	65	3	19	43
Rare diseases	94	11	30	53	145	17	46	82
Other	158	38	25	95	243	58	38	147
Innovative Pharmaceuticals	2,326	916	575	835	3,586	1,411	889	1,286
Established products	655	168	121	366	1,009	259	186	564
<i>Coreg</i>	29	29	-	-	45	45	-	-
<i>Hepsera</i>	18	-	-	18	28	-	-	28
<i>Imigran/Imitrex</i>	46	27	13	6	71	42	20	9
<i>Lamictal</i>	132	67	23	42	203	103	35	65
<i>Lovaza</i>	24	24	-	-	37	37	-	-
<i>Requip</i>	23	-	7	16	35	-	10	25
<i>Serevent</i>	24	11	9	4	37	17	14	6
<i>Seroxat/Paxil</i>	43	(7)	9	41	66	(11)	14	63
<i>Valtrex</i>	46	6	7	33	71	9	11	51
<i>Zeffix</i>	33	1	1	31	51	1	2	48
Other	237	10	52	175	365	16	80	269
Global Pharmaceuticals	2,981	1,084	696	1,201	4,595	1,670	1,075	1,850
HIV	559	308	172	79	860	474	265	121
<i>Combivir</i>	9	3	2	4	13	4	3	6
<i>Epzicom/Kivexa</i>	185	67	80	38	284	102	123	59
<i>Lexiva/Agenerase</i>	18	10	3	5	29	16	5	8
<i>Selzentry</i>	31	15	13	3	48	23	20	5
<i>Tivicay</i>	145	95	37	13	224	147	57	20
<i>Triumeq</i>	149	109	31	9	229	168	48	13
<i>Trizivir</i>	7	2	4	1	10	3	6	1
Other	15	7	2	6	23	11	3	9
Pharmaceuticals	3,540	1,392	868	1,280	5,455	2,144	1,340	1,971
Vaccines	814	240	274	300	1,253	369	422	462
<i>Bexsero</i>	30	2	24	4	46	3	37	6
<i>Boostrix</i>	96	52	31	13	148	81	47	20
<i>Cervarix</i>	18	1	9	8	27	1	14	12
<i>Fluarix, FluLaval</i>	7	(4)	-	11	10	(7)	-	17
Hepatitis	121	58	37	26	187	90	57	40
<i>Infanrix, Pediarix</i>	187	64	81	42	288	99	125	64
<i>Menveo</i>	43	25	7	11	65	39	10	16
<i>Rabipur/Rabivert</i>	15	5	6	4	23	7	10	6
<i>Rotarix</i>	101	30	15	56	156	46	23	87
<i>Synflorix</i>	77	-	8	69	119	-	12	107
Other	119	7	56	56	184	10	87	87
	4,354	1,632	1,142	1,580	6,708	2,513	1,762	2,433

Pharmaceuticals and Vaccines turnover

Six months ended 30 June 2015

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Respiratory	2,875	1,287	761	827	4,399	1,969	1,165	1,265
<i>Anoro Ellipta</i>	27	21	5	1	41	32	7	2
<i>Avamys/Veramyst</i>	130	13	39	78	199	20	60	119
<i>Flixotide/Flovent</i>	312	183	49	80	477	280	75	122
<i>Relvar/Breo Ellipta</i>	94	33	35	26	144	50	54	40
<i>Seretide/Advair</i>	1,858	876	558	424	2,844	1,341	854	649
<i>Ventolin</i>	321	159	60	102	491	243	92	156
Other	133	2	15	116	203	3	23	177
Cardiovascular, metabolic and urology (CVMU)	460	185	134	141	704	283	205	216
<i>Avodart</i>	371	122	132	117	568	187	202	179
Other	89	63	2	24	136	96	3	37
Immuno-inflammation	116	106	7	3	178	162	11	5
<i>Benlysta</i>	107	97	7	3	164	148	11	5
Other	9	9	-	-	14	14	-	-
Oncology	235	91	69	75	360	139	106	115
Other pharmaceuticals	1,067	103	287	677	1,633	158	439	1,036
Dermatology	214	22	71	121	328	34	109	185
<i>Augmentin</i>	283	-	88	195	433	-	135	298
Other anti-bacterials	89	3	28	58	136	5	42	89
Rare diseases	185	23	62	100	283	35	95	153
Other	296	55	38	203	453	84	58	311
Innovative Pharmaceuticals	4,753	1,772	1,258	1,723	7,274	2,711	1,926	2,637
Established products	1,305	331	253	721	1,997	507	387	1,103
<i>Coreg</i>	56	56	-	-	86	86	-	-
<i>Hepsera</i>	40	-	-	40	61	-	-	61
<i>Imigran/Imitrex</i>	84	45	26	13	129	69	40	20
<i>Lamictal</i>	259	130	46	83	396	199	70	127
<i>Lovaza</i>	52	52	-	-	80	80	-	-
<i>Requip</i>	45	1	14	30	69	2	21	46
<i>Serevent</i>	47	21	19	7	72	32	29	11
<i>Seroxat/Paxil</i>	86	(7)	17	76	131	(11)	26	116
<i>Valtrex</i>	88	11	13	64	135	17	20	98
<i>Zeffix</i>	72	1	3	68	110	1	5	104
Other	476	21	115	340	728	32	176	520
Global Pharmaceuticals	6,058	2,103	1,511	2,444	9,271	3,218	2,313	3,740
HIV	1,005	537	326	142	1,538	822	499	217
<i>Combivir</i>	19	6	5	8	29	9	8	12
<i>Epzicom/Kivexa</i>	361	127	162	72	552	194	248	110
<i>Lexiva/Agenerase</i>	34	20	7	7	53	31	11	11
<i>Selzentry</i>	61	29	25	7	93	44	38	11
<i>Tivicay</i>	257	167	66	24	394	256	101	37
<i>Triumeq</i>	230	171	49	10	352	262	75	15
<i>Trizivir</i>	14	4	8	2	21	6	12	3
Other	29	13	4	12	44	20	6	18
Pharmaceuticals	7,063	2,640	1,837	2,586	10,809	4,040	2,812	3,957
Vaccines	1,513	457	498	558	2,315	699	762	854
<i>Bexsero</i>	37	2	30	5	57	3	46	8
<i>Boostrix</i>	162	89	48	25	248	137	73	38
<i>Cervarix</i>	46	2	19	25	70	3	29	38
<i>Fluarix, FluLaval</i>	11	(1)	-	12	16	(2)	-	18
Hepatitis	264	122	78	64	404	187	119	98
<i>Infanrix, Pediarix</i>	373	133	158	82	570	203	242	125
<i>Menveo</i>	54	32	8	14	82	49	12	21
<i>Rabipur/Rabivert</i>	20	8	7	5	31	12	11	8
<i>Rotarix</i>	199	62	32	105	305	95	49	161
<i>Synflorix</i>	137	-	17	120	210	-	26	184
Other	210	8	101	101	322	12	155	155
	8,576	3,097	2,335	3,144	13,124	4,739	3,574	4,811

Consumer Healthcare turnover

Three months ended 30 June 2015

	Total £m	Total \$m
Wellness	740	1,138
Oral health	462	712
Nutrition	165	254
Skin health	142	218
	<u>1,509</u>	<u>2,322</u>

	Total £m	Total \$m
US	360	553
Europe	470	723
International	679	1,046
	<u>1,509</u>	<u>2,322</u>

Corporate and other unallocated turnover was £25 million (\$35 million) for the three months ended 30 June 2015.

Consumer Healthcare turnover

Six months ended 30 June 2015

	Total £m	Total \$m
Wellness	1,333	2,039
Oral health	947	1,449
Nutrition	347	531
Skin health	263	402
	<u>2,890</u>	<u>4,421</u>

	Total £m	Total \$m
US	690	1,055
Europe	834	1,276
International	1,366	2,090
	<u>2,890</u>	<u>4,421</u>

Corporate and other unallocated turnover was £44 million (\$65 million) for the six months ended 30 June 2015.

Balance sheet

	30 June 2015 £m	30 June 2015 \$m
ASSETS		
Non-current assets		
Property, plant and equipment	9,319	14,631
Goodwill	5,072	7,963
Other intangible assets	16,614	26,084
Investments in associates and joint ventures	85	133
Other investments	1,666	2,616
Deferred tax assets	2,452	3,850
Other non-current assets	794	1,246
Total non-current assets	36,002	56,523
Current assets		
Inventories	4,797	7,531
Current tax recoverable	96	151
Trade and other receivables	5,314	8,343
Derivative financial instruments	90	141
Liquid investments	69	109
Cash and cash equivalents	7,546	11,847
Assets held for sale	204	320
Total current assets	18,116	28,442
TOTAL ASSETS	54,118	84,965
LIABILITIES		
Current liabilities		
Short-term borrowings	(2,472)	(3,881)
Trade and other payables	(8,155)	(12,803)
Derivative financial instruments	(117)	(184)
Current tax payable	(1,827)	(2,869)
Short-term provisions	(1,225)	(1,923)
Total current liabilities	(13,796)	(21,660)
Non-current liabilities		
Long-term borrowings	(14,696)	(23,073)
Deferred tax liabilities	(1,721)	(2,702)
Pensions and other post-employment benefits	(3,143)	(4,935)
Other provisions	(469)	(736)
Derivative financial instruments	(7)	(11)
Other non-current liabilities	(9,734)	(15,282)
Total non-current liabilities	(29,770)	(46,739)
TOTAL LIABILITIES	(43,566)	(68,399)
NET ASSETS	10,552	16,566
EQUITY		
Share capital	1,339	2,102
Share premium account	2,792	4,384
Retained earnings	556	873
Other reserves	2,133	3,348
Shareholders' equity	6,820	10,707
Non-controlling interests	3,732	5,859
TOTAL EQUITY	10,552	16,566

US dollar amounts shown above are a convenience transaction of the sterling amounts.